New antidepressant study for adults with major depression
Treatments studied
Part of Mental health clinical trials.
This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can safely and effectively reduce depression symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with major depressive disorder (MDD), and your current episode has lasted at least 3 months (first episode) or at least 1 month (recurrent).
- You have moderate to severe depression, as measured by a standard depression rating scale.
- If you are currently taking antidepressants, you must be willing to stop them (after a washout period) and avoid other psychiatric medications during the trial.
- You must not have had a poor response to two or more antidepressants in a prior episode, and you must not be at high risk of suicide.
- You agree to avoid driving and operating heavy machinery while on the study drug and for 2 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication, KH607, against an existing antidepressant (vortioxetine) to see which is more effective and safer for adults with moderate-to-severe depression. Participants will receive one of the two treatments for several weeks, with the option to continue in a longer-term phase if they respond well.
This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
This study tests a new combination of two medications (dextromethorphan and bupropion) as a treatment for major depressive disorder. It may be an option if you have not already tried many antidepressants that didn't work.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.